CarePlus HEALTH PLANS

**Medicare Advantage and Dual Eligible Special Needs Plans Prior Authorization and Notification List**

We have updated our CarePlus Health Plans Prior Authorization and Notification List for CarePlus Medicare Advantage (MA) and Dual Eligible Special Needs (D-SNP) plans.

Please note the term "prior authorization" (precertification, preadmission), when used in this communication, is defined as a process through which the physician or other healthcare provider is required to obtain advance approval from the plan as to whether an item or service will be covered.

"Notification" refers to the process by which the physician or other healthcare provider notifies CarePlus of the intent to provide an item or service. CarePlus requests notification, as it helps coordinate care for CarePlus-covered patients. This process is distinguished from prior authorization. CarePlus does not issue an approval or denial for notifications.

The list details services and medication (i.e., medications that are delivered in the physician's office, clinic, outpatient or home setting) that require prior authorization prior to being provided or administered. Services must be provided according to Medicare coverage guidelines established by the Centers for Medicare & Medicaid Services (CMS). According to the guidelines, all medical care, services, supplies and equipment must be medically necessary. You can review Medicare coverage guidelines on the CMS website.

To view Humana's medical coverage policies, please visit Humana's Medical and Pharmacy Coverage Policies website.

**Investigational and experimental procedures and devices usually are not covered benefits. Please consult the patient's Evidence of Coverage or contact CarePlus for confirmation of coverage.**

**Important notes:**

- **CarePlus Medicare Advantage (MA) health maintenance organization (HMO):** The full list of prior authorization requirements applies to your patients with CarePlus MA HMO coverage.
- For procedures or services that are investigational or experimental (or that may have limited benefit coverage), or for any service not on our prior authorization list (PAL), you can request a predetermination on behalf of the patient prior to providing the service. You may be contacted if additional information is needed.
    - Initiate a predetermination for medical services by submitting a fax or telephone request:
        - Submit by fax: 888-447-3430.
            - When submitting a predetermination request by fax, please write "predetermination" on your request.
        - Submit by calling 866-220-5448, Monday – Friday, 8 a.m. to 5 p.m., Eastern time
            - When requesting a predetermination by phone, please advise CarePlus you're requesting a "predetermination."

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

**Please note that urgent/emergent services do not require referrals or prior authorization.**

Not obtaining prior authorization for a service could result in financial penalties for the practice and reduced benefits for the patient based on the healthcare provider's contract and the patient's Evidence of Coverage. Services or medication provided without prior authorization may be subject to retrospective medical necessity review. We recommend that an individual practitioner making a specific request for services or medication verify benefits and prior authorization requirements with CarePlus prior to providing services.

**New rule improves the prior authorization process**

Effective Jan. 1, 2026, the Centers for Medicare & Medicaid Services (CMS) requires prior authorization decisions within 7 days for requests for medical items/services. Accordingly, supporting clinical information must be submitted at the time of prior authorization requests. Failure to do so may result in a delayed or adverse decision. Adherence to this process should begin immediately.

**Information required for a prior authorization request or notification may include, but is not limited to, the following:**

- Patient name, date of birth and CarePlus member ID number
- Date of actual service or hospital admission
- Healthcare Common Procedure Coding System (HCPCS) code(s) and diagnosis codes (primary and secondary) (up to a maximum of 6 per authorization request)
- Service location
    - Inpatient (acute hospital, skilled nursing or hospice)
    - Outpatient (telehealth, office, home, off-campus outpatient hospital, on-campus outpatient hospital or ambulatory surgery center)
- Tax Identification Number (TIN), National Provider Identifier (NPI) of facility where service is being rendered, and TIN and NPI number of the provider performing the service
- Caller/requester's name and phone number and attending physician's phone number
- Relevant clinical information

Submitting all relevant clinical information at the time of the request will help expedite the determination. If additional clinical information is required, a CarePlus representative will contact the individual who submitted the prior authorization request and request the specific information needed to complete the authorization process.

**How to request prior authorization:**

**Except where noted by links on the following pages, prior authorization requests for medical services may be initiated:** Choose from the following options to submit a request for prior authorization:

- Submit the request on the Availity Essentials™ website.
- Complete the Health Services Prior Authorization Form and fax it (and a cover sheet) to the appropriate fax number:
    - Broward and Palm Beach counties: 866-832-2678
    - Miami-Dade County: 888-447-3430
    - All other counties: 888-634-3521

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

- Call the CarePlus Health Plans Utilization Management department at 866-220-5448, Monday – Friday, 8 a.m. to 5 p.m., Eastern time.

**Please note:** Online prior authorization requests are encouraged. For certain PAL services requested via Availity Essentials™, healthcare providers have an option to complete a questionnaire. Answers to the questionnaire could lead to real-time approval. If approval is not provided immediately, the information on the questionnaire may help CarePlus with the review.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

**Medicare Advantage and Dual Medicare-Medicaid Plans**

**Preauthorization and Notification List**

Effective Date: July 1, 2026

Revision Date: November 18, 2026

## Medicare Advantage and Dual Medicare-Medicaid Plan Medication Preauthorization List

To request preauthorization: If the prescription drug is billed, dispensed and administered by a physician's office, infusion clinic or outpatient facility, please fax the request to 888-447-3430.

If the prescription drug is billed and shipped from a retail pharmacy to a physician's office or facility, please fax the request to CarePlus Health Plans Pharmacy at 877-486-2621.

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Abecma intravenous suspension | idecabtagene vicleucel | Q2055 |
| Abraxane*,† | paclitaxel-nab*,† | J9264 |
| Actemra IV† | tocilizumab† | J3262 |
| Adakveo | crizanlizumab-tmca | J0791 |
| Adcetris | brentuximab vedotin | J9042 |
| Adstiladrin | nadofaragene firadenovec-vncg | J9029 |
| Aduhelm | aducanumab-avwa | J0172 |
| Adzynma | ADAMTS13, recombinant-krhn | J7171 |
| Akynzeo IV | fosnetupitant and palonosetron | J1454 |
| Aldurazyme | laronidase | J1931 |
| Alimta* | pemetrexed* | J9305 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Alyglo† | immune globulin intravenous, human-stwk† | J1552 |
| Alymsys† | bevacizumab-maly† | Q5126 |
| Amondys-45 | casimersen | J1426 |
| Amtagvi* | lifileucel* | C9399, J3490, J9999 |
| Amvuttra | vutrisiran | J0225 |
| Anktiva | nogapendekin alfa inbakicept-pmln | J9028 |
| Aphexda | motixafortide | J2277 |
| Aralast NP*,† | alpha 1-proteinase inhibitor*,† | J0256 |
| Aranesp† | darbepoetin alfa† | J0881 |
| Armlupeg† | pegfilgrastim-unne† | Q5169 |
| Asceniv† | immune globulin† | J1554 |
| Asparlas | calaspargase pegol-mknl | J9118 |
| Aucatzyl | obecabtagene autoleucel | Q2058 |
| Aukelso*,† | denosumab-kyqq*,† | Q5161 |
| Avastin† (authorization only required for oncology/chemotherapy use) | bevacizumab† | C9257, J9035 |
| Aveed | testosterone undecanoate | J3145 |
| Avlayah | tividenofusp alfa-eknm | J1757 |
| Avopef | etoposide | J9186 |
| Avsola† | infliximab-axxq† | Q5121 |
| Avtozma IV*,† | tocilizumab-anoh*,† | Q5156 |
| Axtle* | pemetrexed* | J9292 |
| Azedra | iobenguane I 131 | A9590 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Bavencio | avelumab | J9023 |
| Beizray | docetaxel-albumin | J9174 |
| Beleodaq | belinostat | J9032 |
| Belrapzo* | bendamustine hydrochloride* | J9036 |
| Bendamustine* | bendamustine hydrochloride* | J9036 |
| bendamustine (Apotex) | bendamustine hydrochloride | J9058 |
| bendamustine (Baxter) | bendamustine hydrochloride | J9059 |
| Bendeka | bendamustine hydrochloride | J9034 |
| Benlysta | belimumab | J0490 |
| Beovu† | brolucizumab-dbll† | J0179 |
| Berinert† | c1 esterase inhibitor† | J0597 |
| Besponsa | inotuzumab ozogamicin | J9229 |
| Bexlutry* | lutetium Lu 177 dotatate* | A9699, J3490 |
| Bildyos*,† | denosumab-nxxp*,† | Q5162 |
| Bilprevda*,† | denosumab-nxxp*,† | Q5162 |
| Bivigam† | immune globulin† | J1556 |
| Bizengri | zenocutuzumab-zbco | J9382 |
| Bkemv IV† | eculizumab-aeeb† | Q5152 |
| Blenrep | belantamab mafodotin-blmf | J9053 |
| Blincyto | blinatumomab | J9039 |
| **Blood-clotting factors (see list on Pages 23 to 25)** | | |
| Bomyntra*,† | denosumab-bnht*,† | Q5158 |
| bortezomib* | bortezomib* | J9041 |
| bortezomib (Dr. Reddy's) | bortezomib | J9046 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| bortezomib (Fresenius Kabi) | bortezomib | J9048 |
| bortezomib (Hospira) | bortezomib | J9049 |
| bortezomib (Maia) | bortezomib | J9051 |
| Boruzu | bortezomib | J9054 |
| Bosaya*,† | denosumab-kyqq*,† | Q5161 |
| Botox | onabotulinumtoxinA | J0585 |
| Breyanzi* | lisocabtagene maraleucel* | Q2054 |
| Brineura | cerliponase alfa | J0567 |
| Briumvi† | ublituximab-xiiy† | J2329 |
| Byooviz† | ranibizumab-nuna intravitreal solution† | Q5124 |
| Carvykti | ciltacabtagene autoleucel | Q2056 |
| Casgevy | exagamglogene autotemcel | J3392 |
| Cerezyme† | imiglucerase† | J1786 |
| Cimerli† | ranibizumab-eqrn† | Q5128 |
| Cimzia† | certolizumab pegol† | J0717 |
| Cinqair | reslizumab | J2786 |
| Cinryze† | C1 esterase inhibitor† | J0598 |
| Cligavyx* | fulvestrant* | C9399, J3490, J9999 |
| Columvi | glofitamab-gxbm | J9286 |
| Conexxence*,† | denosumab-bnht*,† | Q5158 |
| Cosela | trilaciclib | J1448 |
| Cosentyx IV† | secukinumab† | C9166, J3247 |
| Crysvita | burosumab-twza | J0584 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Cutaquig† | immune globulin† | J1551 |
| Cuvitru† | immune globulin† | J1555 |
| Cyramza | ramucirumab | J9308 |
| Danyelza | naxitamab-gqgk | J9348 |
| Darzalex | daratumumab | J9145 |
| Darzalex Faspro | daratumumab and hyaluronidase-fihj | J9144 |
| Datroway | datopotamab-deruxtecan | J9011 |
| Dawnzera*,† | donidalorsen*,† | C9399, J3490 |
| Daxxify | daxibotulinumtoxinA-lanm | J0589 |
| Decnupaz* | pivekimab sunirine-pvzy* | C9313, J3490, J3590, J9999 |
| Defitelio* | defibrotide sodium* | C9399, J3490 |
| Docivyx | docetaxel | J9172 |
| Doxil | doxorubicin HCL liposome injection | Q2050 |
| Dysport | abobotulinumtoxin A | J0586 |
| Elahere | mirvetuximab soravtansine-gynx | J9063 |
| Elaprase | idursulfase | J1743 |
| Elelyso | taliglucerase alfa | J3060 |
| Elevidys | delandistrogene moxeparvovec-rokl | J1413 |
| Elfabrio IV | pegunigalsidase alfa-iwxj | J2508 |
| Elrexfio | elranatamab-bcmm | J1323 |
| Elzonris | tagraxofusp-erzs | J9269 |
| Empaveli* | pegcetacoplan* | C9399, J3490 |
| Empliciti | elotuzumab | J9176 |
| Emrelis IV | telisotuzumab vedotin-tllv | J9326 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

972405FL0326 FLHMZCJEN0726C_C

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Encelto | revakinagene taroretcel-lwey | J3403 |
| Enhertu | fam-trastuzumab deruxtecan-nxki | J9358 |
| Enjaymo | sutimlimab-jome | J1302 |
| Enspryng* | satralizumab-mwge* | C9399, J3490, J3590 |
| Entyvio IV† | vedolizumab† | J3380 |
| Enzeevu† | aflibercept-abzv† | Q5149 |
| Epkinly | epcoritamab-bysp | J9321 |
| Epogen*,† | epoetin alfa*,† | J0885 |
| Epysqli IV† | eculizumab-aagh† | Q5151 |
| Erbitux | cetuximab | J9055 |
| Erwinase* | crisantaspase* | J9019 |
| Euflexxa† | sodium hyaluronate† | J7323 |
| Evdi* | trabectedin* | C9312, J3490, J9999 |
| Evenity† | romosozumab-aqqg† | J3111 |
| Evkeeza† | evinacumab-dgnb† | J1305 |
| Exdensur† | depemokimab-ulaa† | J2361 |
| Exondys 51 | eteplirsen | J1428 |
| Eylea† | aflibercept† | J0178 |
| Eylea HD† | aflibercept† | J0177 |
| Fabrazyme | agalsidase beta | J0180 |
| Fasenra | benralizumab | J0517 |
| Faslodex | fulvestrant | J9395 |
| Favlyxa | fluorouracil | J9191 |
| Fayuvi* | rebisufligene etisparvovec-hopf* | C9399, J3490, J3590 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Feraheme† | ferumoxytol† | Q0138 |
| Filkri† | filgrastim-laha† | Q5172 |
| Firazyr*,† | icatibant*,† | J1744 |
| Flebogamma DIF* | immune globulin* | J1572 |
| Folotyn* | pralatrexate* | J9307 |
| Fulphila | pegfilgrastim-jmdb | Q5108 |
| fulvestrant (Fresenius Kabi) | fulvestrant | J9394 |
| fulvestrant (Teva) | fulvestrant | J9393 |
| Fyarro | sirolimus protein-bound particles for injectable suspension | J9331 |
| Fylnetra† | pegfilgrastim-pbbk† | Q5130 |
| GamaSTAN* | immune globulin* | J1460, J1560 |
| GamaSTAN S/D* | immune globulin* | J1460, J1560 |
| Gamifant | emapalumab-lzsg | J9210 |
| Gammagard* | immune globulin* | J1569 |
| Gammagard ERC* | immune globulin, human* | J1566, J1569 |
| Gammagard S/D* | immune globulin* | J1566 |
| Gammaked* | immune globulin* | J1561 |
| Gammaplex† | immune globulin† | J1557 |
| Gamunex-C* | immune globulin* | J1561 |
| Gazyva | obinutuzumab | J9301 |
| Gel-One† | sodium hyaluronate† | J7326 |
| Gelsyn-3† | sodium hyaluronate† | J7328 |
| Genglycos* | pariglasgene brecaparvovec-opnr* | C9399, J3490, J3590 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.
972405FL0326 FLHMZCJEN0726C_C

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| GenVisc 850† | sodium hyaluronate† | J7320 |
| Givlaari | givosiran | J0223 |
| Glassia† | alpha 1-proteinase inhibitor† | J0257 |
| Granix† | tbo-filgrastim† | J1447 |
| Haegarda | c1 esterase inhibitor subcutaneous | J0599 |
| Herceptin IV† | trastuzumab† | J9355 |
| Herceptin Hylecta† | trastuzumab and hyaluronidase-oysk† | J9356 |
| Hercessi IV† | trastuzumab-strf † | Q5146 |
| Herzuma† | trastuzumab-pkrb† | Q5113 |
| Hizentra | immune globulin | J1559 |
| Hyalgan*,† | sodium hyaluronate*,† | J7321 |
| Hymovis*,† | sodium hyaluronate*,† | J7322 |
| Hymovis ONE*,† | hyaluronate*,† | C9399, J3490 |
| Hyqvia† | immune globulin† | J1575 |
| Ilaris | canakinumab | J0638 |
| Ilumya† | tildrakizumab-asmn† | J3245 |
| Iluvien | fluocinolone acetonide | J7313 |
| Imaavy† | nipocalimab-aahu† | J9256 |
| Imdelltra | tarlatamab-dlle | J9026 |
| Imfinzi† | durvalumab† | J9173 |
| Imjudo† | tremelimumab-actl† | J9347 |
| Imlygic | talimogene laherparepvec | J9325 |
| Imuldosa IV*,† | ustekinumab-srlf*,† | Q5098 |
| Inflectra | infliximab-dyyb | Q5103 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.
972405FL0326 FLHMZCJEN0726C_C

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| infliximab | infliximab | J1745 |
| Injectafer† | ferric carboxymaltose† | J1439 |
| Inlexzo intravesical system | gemcitabine | J9183 |
| Isembyld* | apitegromab-mstn* | C9399, J3490, J3590 |
| Istodax | romidepsin | J9319 |
| Itvisma | onasemnogene abeparvovec-brve | J3405 |
| Ixempra | ixabepilone | J9207 |
| Izervay | avacincaptad pegol intravitreal solution | J2782 |
| Jelmyto* | mitomycin* | J9281 |
| Jemperli | dostarlimab-gxly | J9272 |
| Jevtana | cabazitaxel | J9043 |
| Jobevne† | bevacizumab-nwgd† | Q5160 |
| Jubbonti*,† | denosumab-bbdz*,† | Q5136 |
| Jubereq*,† | denosumab-desu*,† | Q5166 |
| Kadcyla | ado-trastuzumab emtansine | J9354 |
| Kalbitor† | ecallantide† | J1290 |
| Kanjinti† | trastuzumab-anns† | Q5117 |
| Kanuma | sebelipase alfa | J2840 |
| Kebilidi* | eladocagene exuparvovec-tneq* | C9399, J3490, J3590 |
| Keytruda† | pembrolizumab† | J9271 |
| Keytruda Qlex† | pembrolizumab and berahyaluronidase alfa-pmph† | J9277 |
| Khapzory | levoleucovorin | J0642 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.
972405FL0326 FLHMZCJEN0726C_C

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Kimmtrak | tebentafusp-tebn | J9274 |
| Kisunla | donanemab-azbt | J0175 |
| Korsuva | difelikefalin | J0879 |
| Kresladi* | marnetegragene autotemcel* | C9399, J3490, J3590 |
| Krystexxa | pegloticase | J2507 |
| Kymriah | tisagenlecleucel | Q2042 |
| Kyprolis | carfilzomib | J9047 |
| Kyxata | carboplatin | J9278 |
| Lamzede | velmanase alfa-tycv | J0217 |
| lanreotide* | lanreotide* | J1930 |
| lanreotide (Cipla) | lanreotide | J1932 |
| Lantidra* | donislecel-jujn* | C9399, J3490, J3590 |
| Lemtrada† | alemtuzumab† | J0202 |
| Lenmeldy | atidarsagene autotemcel | J3391 |
| Leqembi | lecanemab-irmb | J0174 |
| Leqembi Iqlik* | lecanemab-irmb* | C9399, J3490, J3590 |
| Leqvio† | inclisiran† | J1306 |
| Leukine | sargramostim | J2820 |
| Levoleucovorin* | levoleucovorin calcium* | J0641 |
| Libtayo | cemiplimab-rwlc | J9119 |
| Loargys | pegzilarginase-nbln | J1818 |
| Loqtorzi | toripalimab-tpzi | J3263 |
| Lucentis† | ranibizumab† | J2778 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.
972405FL0326 FLHMZCJEN0726C_C

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Lumizyme | alglucosidase alfa | J0221 |
| Lumvoa* | veligrotug-vvze* | C9399, J3490, J3590 |
| Lunsumio* | mosunetuzumab-axgb* | J9350 |
| Lunsumio Velo* | mosunetuzumab-axgb* | J9350 |
| Lutathera† | lutetium Lu 177 dotatate† | A9513 |
| Luxturna | voretigene neparvovec-rzyl | J3398 |
| Lyfgenia | lovotibeglogene autotemcel | J3394 |
| Lymphir | denileukin diftitox-cxdl | J9161 |
| Lynozyfic | linvoseltamab-gcpt | J9601 |
| Lytenava*,† | bevacizumab-vikg*,† | C9399, J3490, J3590 |
| Margenza | margetuximab-cmkb | J9353 |
| Mepsevii | vestronidase alfa-vjbk | J3397 |
| Mircera | methoxy polyethylene glycol – epoetin beta | J0888 |
| Monjuvi | tafasitamab-cxix | J9349 |
| Monoferric† | ferric derisomaltose† | J1437 |
| Mozobil* | plerixafor* | J2562 |
| Mvasi | bevacizumab-awwb | Q5107 |
| Mylotarg | gemtuzumab ozogamicin | J9203 |
| Myobloc | rimabotulinumtoxinB | J0587 |
| Naglazyme | galsulfase | J1458 |
| Neulasta* | pegfilgrastim* | J2506 |
| Neulasta Onpro* | pegfilgrastim* | J2506 |
| Neupogen† | filgrastim† | J1442 |
| Nexviazyme | avalglucosidase alfa-ngpt | J0219 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Ngenla* | somatrogon-ghla* | C9399, J3490, J3590 |
| Niktimvo IV | axatilimab-csfr | J9038 |
| Nivestym† | filgrastim-aafi† | Q5110 |
| Nplate | romiplostim | J2802 |
| Nucala | mepolizumab | J2182 |
| Nufymco† | ranibizumab-leyk† | Q5168 |
| Nulibry | fosdenopterin | J1809 |
| Nypozi† | filgrastim-txid† | Q5148 |
| Nyvepria† | pegfilgrastim-apgf† | Q5122 |
| Ocrevus | ocrelizumab | J2350 |
| Ocrevus Zunovo | ocrelizumab and hyaluronidase-oscq | J2351 |
| Octagam | immune globulin | J1568 |
| Ogivri | trastuzumab-dkst | Q5114 |
| Omisirge | omidubicel-onlv | J3406 |
| Omvoh IV*,† | mirikizumab-mrkz*,† | J2267 |
| Onapgo SQ cartridge* | apomorphine hydrochloride* | C9399, J3490 |
| Oncaspar | pegaspargase | J9266 |
| Onivyde | irinotecan liposome injection | J9205 |
| Onpattro | patisiran | J0222 |
| Ontruzant† | trastuzumab-dttb† | Q5112 |
| Opdivo† | nivolumab† | J9299 |
| Opdivo Qvantig | nivolumab hyaluronidase-nvhy | J9289 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Opdualag | nivolumab and relatlimab-rmbw injection | J9298 |
| Orencia IV† | abatacept† | J0129 |
| Osenvelt*,† | denosumab-bmwo*,† | Q5157 |
| Ospomyv*,† | denosumab-dssb*,† | Q5159 |
| Osvyrti*,† | denosumab-desu*,† | Q5166 |
| Otarmeni* | lunsotogene parvec-cwha* | C9399, J3490, J3590 |
| Otulfi IV | ustekinumab-aauz | Q9999 |
| Oxlumo | lumasiran | J0224 |
| Ozurdex | dexamethasone intravitreal implant | J7312 |
| paclitaxel protein-bound*,† | paclitaxel protein-bound*,† | J9264 |
| Padcev | enfortumab vedotin-ejfv | J9177 |
| Palynziq* | pegvaliase-pqpz* | C9399, J3490, J3590 |
| Panhematin | hemin | J1640 |
| Panzyga† | immune globulin† | J1576 |
| Papzimeos | zopapogene imadenovec-drba | J3404 |
| Pasatru* | garetosmab-grts* | C9399, J3490, J3590 |
| Pavblu† | aflibercept-ayyh† | Q5147 |
| Pedmark IV solution | sodium thiosulfate | J0208 |
| Pemetrexed | pemetrexed | J9305 |
| Pemetrexed (Accord) | pemetrexed | J9296 |
| Pemetrexed (Bluepoint) | pemetrexed | J9322 |
| Pemetrexed (Sandoz) | pemetrexed | J9297 |
| Pemetrexed (Teva) | pemetrexed | J9314 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.
972405FL0326 FLHMZCJEN0726C_C

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| pemetrexed disodium (Hospira) | pemetrexed disodium | J9294 |
| pemetrexed ditromethamine | pemetrexed ditromethamine | J9323 |
| Pemfexy | pemetrexed injection | J9304 |
| Pemrydi RTU | pemetrexed | J9324 |
| Perjeta | pertuzumab | J9306 |
| Phesgo | pertuzumab, trastuzumab, and hyaluronidase-zzxf | J9316 |
| Piasky† | crovalimab-akkz† | J1307 |
| plerixafor* | plerixafor* | J2562 |
| Pluvicto | lutetium Lu 177 vipivotide tetraxetan | A9607 |
| Polivy | polatuzumab vedotin-piiq | J9309 |
| Pombiliti | cipaglucosidase alfa-atga | J1203 |
| Ponlimsi† | denosumab-adet† | Q5173 |
| Portrazza | necitumumab | J9295 |
| Poteligeo | mogamulizumab-kpkc | J9204 |
| pralatrexate IV* | pralatrexate* | J9307 |
| Prevymis IV* | letermovir* | C9399, J3490 |
| Prialt | ziconotide | J2278 |
| Privigen | immune globulin | J1459 |
| Procrit* | epoetin alfa* | J0885 |
| Prolastin-C*, † | alpha 1-proteinase inhibitor*,† | J0256 |
| Provenge | sipuleucel-T | Q2043 |
| Pyzchiva IV† | ustekinumab-ttwe† | Q9997 |
| Qalsody | tofersen | J1304 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.
972405FL0326 FLHMZCJEN0726C_C

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Qivigy † | immune globulin intravenous, human-kthm† | J1577, J1599 |
| Qutenza | capsaicin/skin cleanser | J7336 |
| Radicava | edaravone | J1301 |
| Reblozyl† | luspatercept-aamt† | J0896 |
| Releuko† | filgrastim-ayow injection† | Q5125 |
| Remicade | infliximab | J1745 |
| Remodulin* | treprostinil (injection)* | J3285 |
| Renflexis† | infliximab-abda† | Q5104 |
| Retacrit | epoetin alfa-epbx | Q5106 |
| Rethymic* | allogeneic processed thymus tissue-agdc* | C9399, J3490, J3590 |
| Revtorpyk* | gedatolisib* | C9399, J3490, J9999 |
| Riabni† | rituximab-arrx† | Q5123 |
| Rituxan Hycela† | rituximab; hyaluronidase human† | J9311 |
| Rituxan IV† | rituximab† | J9312 |
| Rolvedon† | eflapegrastim-xnst† | J1449 |
| romidepsin | romidepsin | J9318 |
| Ruconest† | C1 esterase inhibitor† | J0596 |
| Ruxience† | rituximab-pvvr† | Q5119 |
| Rybrevant Faspro | amivantamab and hyaluronidase-lpuj | J9062 |
| Rybrevant IV | amivantamab-vmjw | J9061 |
| Rylaze | asparaginase erwinia chrysanthemi (recombinant)-rywn | J9021 |
| Ryoncil | remestemcel-L-rknd | J3402 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.
972405FL0326 FLHMZCJEN0726C_C

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Ryplazim | plasminogen, human-tvmh | J2998 |
| Rystiggo† | rozanolixizumab-noli† | J9333 |
| Rytelo IV | imetelstat | J0870 |
| Ryzneuta† | efbemalenograstim alfa-vuxw† | J9361 |
| Sajazir* | icatibant* | J1744 |
| Sandostatin LAR | octreotide | J2353 |
| Saphnelo intravenous solution | anifrolumab-fnia | J0491 |
| Sarclisa | isatuximab-irfc | J9227 |
| Sarclisa Escena* | isatuximab-irfc* | C9399, J3490, J3590, J9999 |
| Scenesse | afamelanotide | J7352 |
| Selarsdi IV*, † | ustekinumab-aekn*, † | Q9998 |
| Signifor LAR | pasireotide | J2502 |
| Simponi ARIA | golimumab | J1602 |
| Sinuva | mometasone furoate | J7402 |
| Skyrizi IV | risankizumab-rzaa | J2327 |
| Skysona | elivaldogene autotemcel | J3387 |
| Soliris† | eculizumab† | J1299 |
| Somatuline Depot* | lanreotide* | J1930 |
| Spevigo IV | spesolimab-sbzo | J1747 |
| Spinraza | nusinersen | J2326 |
| Starjemza IV*,† | ustekinumab-hmny*,† | Q5164 |
| Stelara (IV) * | ustekinumab* | J3358 |
| Steqeyma IV† | ustekinumab-stba† | Q5099 |
| Stimufend† | pegfilgrastim-fpgk† | Q5127 |
| Stoboclo*,† | denosumab-bmwo*,† | Q5157 |
| Sustol | granisetron | J1627 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Susvimo† | ranibizumab† | J2779 |
| Syfovre | pegcetacoplan | J2781 |
| SynoJoynt† | 1% sodium hyaluronate† | J7331 |
| Synribo | omacetaxine mepesuccinate | J9262 |
| Synvisc*,† | hylan G-F 20*,† | J7325 |
| Takhzyro† | lanadelumab-flyo† | J0593 |
| Talvey | talquetamab-tgvs | J3055 |
| Tecartus | brexucabtagene autoeucel | Q2053 |
| Tecelra | afamitresgene autoleucel | Q2057 |
| Tecentriq† | atezolizumab† | J9022 |
| Tecentriq Hybreza† | atezolizumab and hyaluronidase-tqjs† | J9024 |
| Tecvayli | teclistamab-cqyv | J9380 |
| Tepezza | teprotumumab-trbw | J3241 |
| Tevimbra | tislelizumab-jsgr | J9329 |
| Tezspire* | tezepelumab-ekko* | J2356 |
| Tezspire subcutaneous pen injector* | tezepelumab-ekko* | J2356 |
| Thrombate III | antithrombin III (human) | J7197 |
| Tivdak† | tisotumab vedotin-tftv† | J9273 |
| Tofidence IV† | tocilizumab-bavi† | Q5133 |
| Trazimera | trastuzumab-qyyp | Q5116 |
| Treanda | bendamustine hydrochloride | J9033 |
| Tregzi* | allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq* | C9399, J3490, J3590, J9999 |
| Tremfya IV* | guselkumab* | J1628 |
| Triluron† | hyaluronate sodium† | J7332 |
| Trisenox | arsenic trioxide | J9017 |
| TriVisc† | sodium hyaluronate† | J7329 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.
972405FL0326 FLHMZCJEN0726C_C

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Trodelvy | sacituzumab govitecan-hziy | J9317 |
| Truxima† | rituximab-abbs† | Q5115 |
| Tudriqev* | Vusolimogene oderparepvec-wtpg* | C9399, J3490, J3590, J9999 |
| Tyenne IV† | tocilizumab-aazg† | Q5135 |
| Tyruko† | natalizumab-sztn† | Q5134 |
| Tysabri† | natalizumab† | J2323 |
| Tyvaso | treprostinil (inhaled) | J7686 |
| Tzield | teplizumab-mzwv | J9381 |
| Udenyca* | pegfilgrastim-cbqv* | Q5111 |
| Udenyca Autoinjector* | pegfilgrastim-cbqv* | Q5111 |
| Udenyca Onbody* | pegfilgrastim-cbqv* | Q5111 |
| Ultomiris | ravulizumab-cwvz | J1303 |
| Unituxin* | dinutuximab* | C9399, J3490, J9999 |
| Unloxcyt | cosibelimab-ipdl | J9275 |
| Uplizna† | inebilizumab-cdon† | J1823 |
| Ustekinumab IV*,† | ustekinumab*,† | J3358 |
| Vabysmo† | faricimab-svoa injection† | J2777 |
| Valstar | valrubicin | J9357 |
| Vectibix | panitumumab | J9303 |
| Vegzelma† | bevacizumab-adcd† | Q5129 |
| Velcade* | bortezomib* | J9041 |
| Veopoz | pozelimab-bbfg | J9376 |
| Viltepso | viltolarsen | J1427 |
| Vimizim | elosulfase alfa | J1322 |
| Visco-3*,† | sodium hyaluronate*,† | J7321 |
| Vivimusta | bendamustine hydrochloride | J9056 |
| Voceryq* | doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd* | C9399, J3490, J3590 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Vpriv† | velaglucerase alfa† | J3385 |
| Vyepti† | eptinezumab-jjmr† | J3032 |
| Vyjuvek | beremagene geperpavec-svdt | J3401 |
| Vyloy | zolbetuximab-clzb | J1326 |
| Vyondys 53 | golodirsen | J1429 |
| Vyvgart Hytrulo | efgartigimod alfa and hyaluronidase-qvfc | J9334 |
| Vyvgart IV | efgartigimod alfa-fcab | J9332 |
| Vyxeos | daunorubicin/cytarabine | J9153 |
| Wainua* | eplontersen injection* | C9311, J3490 |
| Waskyra | etuvetidigene autotemcel | J3386 |
| Wezlana IV† | ustekinumab-auub† | Q5138 |
| Wyost*,† | denosumab-bbdz*,† | Q5136 |
| Xembify | immune globulin | J1558 |
| Xenpozyme | olipudase alfa-rpcp | J0218 |
| Xeomin | incobotulinumtoxinA | J0588 |
| Xgeva*,† | denosumab*,† | J0897 |
| Xipere | triamcinolone acetonide | J3299 |
| Xofigo | radium Ra 223 dichloride | A9606 |
| Xolair | omalizumab | J2357 |
| Xtrenbo*,† | denosumab-qbde*,† | Q5167 |
| Yartemlea | narsoplimab-wuug | J1289 |
| Yervoy† | ipilimumab† | J9228 |
| Yesafili† | aflibercept-jbvf† | Q5155 |
| Yescarta | axicabtagene ciloleucel | Q2041 |
| Yesintek IV* | ustekinumab-kfce* | Q5100 |
| Yimmugo† | immune globulin intravenous, human-dira† | J1553 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.
972405FL0326 FLHMZCJEN0726C_C

| Brand-name medication | Generic medication | Codes |
|---|---|---|
| Yondelis | trabectedin | J9352, J9362 |
| Zaltrap | ziv-aflibercept | J9400 |
| Zanvastro* | zilganersen* | C9399, J3490 |
| Zarxio | filgrastim-sndz | Q5101 |
| Zemaira* | alpha 1-proteinase inhibitor* | J0256 |
| Zepzelca | lurbinectedin | J9223 |
| Zevalin | ibritumomab tiuxetan | A9543 |
| Zevaskyn | prademagene zamikeracel | J3389 |
| Ziextenzo† | pegfilgrastim-bmez† | Q5120 |
| Ziihera | zanidatamab-hrii | J9276 |
| Zilretta† | triamcinolone acetonide† | J3304 |
| Zirabev | bevacizumab-bvzr | Q5118 |
| Zoladex | goserelin acetate | J9202 |
| Zolgensma | onasemnogene abeparvovec-xioi | J3399 |
| Zusduri | mitomycin | J9282 |
| Zynlonta | loncastuximab tesirine-lpyl | J9359 |
| Zynteglo | betibeglogene autotemcel | J3393 |
| Zynyz | retifanlimab-dlwr | J9345 |
| **Blood-clotting factors** | | |
| **Brand-name medication** | **Generic medication** | **Codes** |
| Advate* | antihemophilic factor (recombinant)* | J7192 |
| Adynovate | antihemophilic factor (recombinant), PEGylated | J7207 |
| Afstyla | antihemophilic factor (recombinant) single chain | J7210 |
| Alhemo† | concizumab-mtci† | J7173 |
| Alphanate | antihemophilic factor/von Willebrand factor complex (human) | J7186 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.
972405FL0326 FLHMZCJEN0726C_C

| Blood-clotting factors | | |
|---|---|---|
| **Brand-name medication** | **Generic medication** | **Codes** |
| AlphaNine SD | coagulation factor IX (human) | J7193 |
| Alprolix | coagulation factor IX (recombinant) | J7201 |
| Altuviiio | efanesoctocog alfa | J7214 |
| BeneFix* | coagulation factor IX (recombinant)* | J7195 |
| Beqvez | fidanacogene elaparvovec-dzkt | J1414 |
| Coagadex | coagulation factor X (human) | J7175 |
| Corifact | factor XIII concentrate (human) | J7180 |
| Eloctate | antihemophilic factor (recombinant), Fc fusion protein | J7205 |
| Esperoct | antihemophilic factor (recombinant), glycopegylated-exei | J7204 |
| Feiba NF | anti-inhibitor coagulant complex | J7198 |
| Hemgenix | etranacogene dezaparvovec-drlb | J1411 |
| Hemlibra† | emicizumab-kxwh† | J7170 |
| Hemofil M* | antihemophilic factor (human)* | J7190 |
| Humate-P | antihemophilic factor/von Willebrand factor complex (human) | J7187 |
| Hympavzi† | marstacimab-hncq† | J7172 |
| Idelvion | coagulation factor IX (recombinant) | J7202 |
| Ixinity | coagulation factor IX (recombinant) | J7213 |
| Jivi | antihemophilic factor (recombinant), PEGylated-aucl | J7208 |
| Koate-DVI* | antihemophilic factor (human)* | J7190 |
| Kogenate FS* | antihemophilic factor (recombinant)* | J7192 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

| Blood-clotting factors | | |
|---|---|---|
| **Brand-name medication** | **Generic medication** | **Codes** |
| Kovaltry | antihemophilic factor (recombinant) | J7211 |
| NovoEight | turoctocog alfa | J7182 |
| NovoSeven RT | coagulation Factor VIIa, recombinant; eptacog alfa | J7189 |
| Nuwiq | simoctocog alfa | J7209 |
| Obizur | antihemophilic factor (recombinant), porcine sequence | J7188 |
| Profilnine | factor IX complex | J7194 |
| Qfitlia*,† | fitusiran*,† | J7174 |
| Rebinyn | coagulation factor IX (recombinant), GlycoPEGylated | J7203 |
| Recombinate* | antihemophilic factor (recombinant)* | J7192 |
| Rixubis | coagulation factor IX (recombinant) | J7200 |
| Roctavian | valoctocogene roxaparvovec-rvox | J1412 |
| SevenFact intravenous solution | coagulation factor VIIa (recombinant)-jncw; eptacog beta | J7212 |
| Tretten | coagulation factor XIII A-subunit (recombinant) | J7181 |
| Vonvendi | von Willebrand factor (recombinant) | J7179 |
| Wilate | von Willebrand factor/coagulation factor VIII complex (human) | J7183 |
| Xyntha* | antihemophilic factor (recombinant) * | J7185 |
| Xyntha Solofuse* | antihemophilic factor (recombinant) * | J7185 |

* All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
†Step therapy required through a CarePlus preferred drug as part of preauthorization.
To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.